Interesting trial.

Long-COVID personalized medicine enters Phase 2 trial using #Temelimab against #HERV virus that was induced during a SARScov2 infection in #LongCovid patients. #Anti_W_ENV
https://www.biopharma-reporter.com/Article/2022/11/22/Long-COVID-personalized-medicine-enters-Phase-2-trial#.Y33omibPgA0.twitter